NDT Advance Access originally published online on March 30, 2006
Nephrology Dialysis Transplantation 2006 21(8):2256-2262; doi:10.1093/ndt/gfl134
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Original Articles: Dialysis and Transplantation
Switching immunosuppression medications after renal transplantation—a common practice
1 Department of Internal Medicine, University of Florida and 2 ProSanos Corporation, La Jolla, California, USA
Correspondence and offprint requests to: Herwig-Ulf Meier-Kriesche, Division of Nephrology, University of Florida College of Medicine, 1600 SW Archer Road, Box 100224, Gainesville, FL 32610-0224, USA. Email: Meierhu{at}medicine.ufl.edu
Background. The rate of change to immunosuppression discharge regimens over time is unknown. We examined the frequency of changes to initial drug treatment regimens and factors associated with a drug change following renal transplantation.
Methods. Scientific Registry of Transplant Recipients data from adult recipients who underwent primary renal transplantation between January 1998 and December 2002 were analysed. The Kaplan–Meier analysis was used to determine the frequency of regimen changes for the most common immunosuppression discharge regimens, type of change, and to examine switching between the calcineurin inhibitors tacrolimus (Tacro) and ciclosporin United States Pharmacopera (USP) modified (CsA). Cox proportional hazard regression was used to examine recipient, donor and transplant characteristics associated with a drug change.
Results. The majority of patients experienced a change to their discharge regimen post-transplantation, and more changes were observed within higher-risk sub-groups of patients. Switching from CsA to Tacro was more common than Tacro to CsA. Significant factors associated with a drug change included those associated with graft loss.
Conclusions. Significant immunosuppression regimen changes occur during the first 4 years post-transplantation. It is possible that early graft survival benefits proven in prospective clinical trials may not translate into long-term success in clinical practice, possibly in part because efficacious regimens are not necessarily maintained long-term.
Keywords: immunosuppression; mycophenolate mofetil; renal transplantation; tacrolimus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. T. van Leeuwen, A. E. Grulich, S. P. McDonald, M. R.E. McCredie, J. Amin, J. H. Stewart, A. C. Webster, J. R. Chapman, and C. M. Vajdic Immunosuppression and Other Risk Factors for Lip Cancer after Kidney Transplantation Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Cole, O. Johnston, C. L. Rose, and J. S. Gill Impact of Acute Rejection and New-Onset Diabetes on Long-Term Transplant Graft and Patient Survival Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 814 - 821. [Abstract] [Full Text] [PDF]
|
|